Is CSLLY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Immunoglobulin recovery at CSL Behring, with revenue (fy26, year to june 2026) at ~US$15.8 billion (down ~1%). The bear case rests on the most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

Immunoglobulin recovery at CSL Behring. Immunoglobulin is CSL's single most important product line, at about US$6.2 billion of FY26 sales, and it was flat for the year as CSL worked down excess US channel inventory and absorbed Medicare Part D redesign effects and some prior-year tender losses.

The most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on. US policy is a second risk: Medicare drug pricing changes, potential pharmaceutical tariffs, and a federal stance that has lowered flu vaccination rates all hit CSL directly, since the US is its largest market. Execution risk is elevated because the company is mid-restructuring with an interim CEO, and a permanent leader may reset strategy, guidance or capital allocation again. China cost-containment measures have already cut albumin sales about 17%, and further volume-based procurement could do more damage. Finally, CSLLY holders carry Australian dollar to US dollar currency exposure on the share price and trade in a thinner OTC market with wider spreads than the ASX line.

Australian biotech known for plasma-derived therapies (CSL Behring), Seqirus vaccines and Vifor iron and kidney drugs.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Immunoglobulin recovery at CSL Behring) stalling in the reported numbers rather than in the narrative, the risk above (the most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CSLLY is the ticker for CSL Limited's sponsored Level 1 American Depositary Receipt, which trades over the counter in the United States. CSL itself is headquartered in Melbourne and its primary listing is on the Australian Securities Exchange under the code CSL. The ADR lets US investors hold an economic interest in CSL shares in US dollars through an ordinary US brokerage account, without opening an Australian account. The depositary bank, Bank of New York Mellon, holds the underlying ordinary shares and issues ADRs against them. Because CSLLY is OTC rather than exchange-listed, trading volume is far lower than on the ASX and bid-ask spreads can be wider.

For many years two CSLLY ADRs represented one CSL ordinary share. In early March 2026 the ADR program issued a 100% ADR stock dividend, effectively a 2-for-1 ADR split, and the price arithmetic since then is consistent with four ADRs per ordinary share. That is why CSLLY trades near US$32 while one ASX share is about A$185, or roughly US$129. Historical charts on sites like Yahoo Finance adjust older ADR prices for this change, so a 52-week range or long-term chart may not line up with prices quoted in older articles. Investors can confirm the current ratio with BNY Mellon's depositary receipt directory or CSL's investor relations site.

CSL earns most of its revenue in US dollars and reports in US dollars, but its shares are priced in Australian dollars on the ASX. CSLLY's US dollar price is essentially the ASX price converted at the current AUD/USD exchange rate and divided by four. If the Australian dollar strengthens against the US dollar, CSLLY rises even if the ASX price is unchanged, and the reverse is also true. Over the past year AUD/USD has moved between roughly 0.65 and 0.72, which is enough to add or subtract several percentage points from returns. The underlying business's earnings are relatively insulated because they are largely dollar based, but the share price translation still adds currency movement.